Labcorp Launches Molecular Residual Disease and Liquid Biopsy Solutions
FDA-authorized liquid biopsy assay PGDx elio® plasma focus™ Dx now available to support treatment selection
BURLINGTON, N.C., April 23, 2025 /PRNewswire/ — Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the expansion of its precision oncology portfolio with two solutions: Labcorp Plasma Detect for clinical use to help assess the risk of disease recurrence in stage III colon cancer patients, and the availability of PGDx elio plasma focus Dx, the first and only kitted, pan-solid tumor liquid biopsy test authorized by the U.S. Food and Drug Administration (FDA) to identify patients who may benefit from targeted treatments.
'Labcorp is dedicated to providing oncologists with a comprehensive portfolio of innovative solutions that enable precise, timely and personalized treatment decisions,' said Shakti Ramkissoon, M.D., Ph.D., vice president, medical lead for oncology at Labcorp. 'With the expansion of our portfolio to include Labcorp Plasma Detect for clinical use and the availability of PGDx elio plasma focus Dx to support patient treatment selection, we're advancing care across the oncology spectrum, solidifying our commitment to transforming cancer diagnostics and improving patient outcomes.'
Labcorp Plasma Detect: Advanced Risk Assessment for Colon Cancer PatientsStage III colon cancer has a nearly 30% recurrence rate within five years. Labcorp Plasma Detect is a blood-based test using whole-genome sequencing (WGS) to detect circulating tumor DNA (ctDNA), indicating the presence of molecular residual disease (MRD).i Patients who are MRD-positive after cancer treatment have a higher risk of recurrence and a poorer prognosis. Labcorp's test detects cancer recurrence risk that conventional methods might miss, helping to identify patients who could benefit from additional treatment or therapy.
Key Features of Labcorp Plasma Detect:
The test is Labcorp's first tumor-informed MRD solution for clinical use to support recurrence risk stratification. Labcorp Plasma Detect launched in 2024 for biopharma use to support exploratory and investigational studies.
The test combines a WGS approach, without the need for a bespoke panel, with proprietary bioinformatics to deliver ctDNA detection down to a limit of detection (LOD95) of 0.005%.
Results are available approximately 14 days after Labcorp receives the initial sample, and seven days for subsequent monitoring time points for each patient.
Labcorp Plasma Detect is currently being evaluated in more than 10 clinical studies in the U.S. and internationally to assess MRD across various cancer types.
Labcorp Plasma Detect will be offered initially through an Early Experience Program, with the intent to expand availability more broadly.
PGDx elio plasma focus Dx Now Available for Use to Aid in Treatment SelectionPGDx elio plasma focus Dx is the first and only kitted pan-solid tumor liquid biopsy test to receive De Novo authorization from the FDA. This assay provides oncologists with a validated tool to assess various solid tumors for targeted treatment selection – all from a simple blood draw.
Key Features of PGDx elio plasma focus Dx:
The kitted model allows clinical laboratories and hospitals to retain control over patient specimens and data for research, care management and other clinical purposes.
As an FDA-authorized assay, PGDx elio plasma focus Dx requires only on-site verification – as opposed to a full validation – enabling more rapid implementation.
Once implemented, this rapid, scalable liquid biopsy genomic test provides actionable findings within a 4-to-5-day turnaround time, from isolated nucleic acid to variant report.
As part of the PGDx elio platform, the kitted model is compatible with FDA-cleared PGDx elio™ tissue complete, enabling seamless, in-house tissue-to-liquid reflexing and efficient comprehensive genomic profiling workflows.
Labcorp at the American Association for Cancer Research (AACR) 2025 Annual MeetingLabcorp will present key studies at the AACR 2025 Annual Meeting, including the clinical use of Labcorp Plasma Detect and performance of PGDx elio plasma focus Dx.
To learn more, or to connect with Labcorp at AACR in Chicago, visit https://oncology.labcorp.com/american-association-cancer-research-annual-meeting-2025
For more information about Labcorp's Oncology solutions, contact us at https://oncology.labcorp.com/contact-us
About Labcorp Labcorp (NYSE: LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. We provide insights and advance science to improve health and improve lives through our unparalleled diagnostics and drug development laboratory capabilities. The company's nearly 70,000 employees serve clients in approximately 100 countries, provided support for more than 75% of the new drugs and therapeutic products approved in 2024 by the FDA, and perform more than 700 million tests annually for patients around the world. Learn more about us at www.labcorp.com.
i The term MRD is often used interchangeably between molecular residual disease and minimal residual disease. Labcorp Plasma Detect detects molecular residual disease, which is defined as the subclinical presence of a cancer-associated biomarker indicating a high risk of recurrence, which cannot be detected by standard imaging techniques. MRD terminology is in accordance with the BLOODPAC Consortium.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Malaysian Reserve
19 minutes ago
- Malaysian Reserve
Significant reliability improvements in 2025: CenterPoint Energy's Greater Houston Resiliency Initiative helps deliver 45% reduction in customer outage minutes across Houston in first half of year
Average customer outage minutes decreased every month in first half of 2025 compared to last year; outage minutes year-to-date are also significantly below the five-year average Number of outages related to trees, branches and other vegetation contacting lines down about 33% compared with the same time period in 2024 Actions taken to strengthen system and improve reliability included historic investment in more storm-resistant poles, automation devices, undergrounding power lines and clearing of hazardous vegetation across service area HOUSTON, July 23, 2025 /PRNewswire/ — CenterPoint Energy today announced significant improvements in reliability for its Houston-area customers, with the total electric service outage minutes reduced by approximately 45% through June 30, 2025, compared to the same period in 2024. The reduction in outages or service interruptions follows the unprecedented series of resiliency actions taken by CenterPoint to strengthen the electric system, improve reliability and reduce the impact and duration of outages, as part of its Greater Houston Resiliency Initiative (GHRI). Additionally, CenterPoint customers across Greater Houston have experienced about 33% fewer outages related to trees, branches, and other vegetation coming in contact with electrical equipment than it did in 2024 over the same time. 'Showing up for our customers is what drives our work every day. This is a significant improvement by any standard. The 45% decrease in outage minutes reflects the significant and real progress being felt by our communities across Greater Houston. Looking ahead, we remain laser-focused on building on the positive impact of our GHRI actions and achieving further resiliency and reliability improvements as we prepare for the reality of more extreme weather and more powerful storms,' said Darin Carroll, Senior Vice President of CenterPoint's Electric Business. Significant improvements in reliability across Greater Houston areaFrom January 1 through June 30, 2025, CenterPoint customers experienced shorter outages, including more than 20 million less outage minutes per month, and a 45% reduction in the duration of outages for individual customers. In addition, outages year-to-date have decreased by 41 million minutes compared to the five-year average since 2020. Since launching the GHRI in July 2024 with a goal of improving the reliability and resiliency of the electric system, CenterPoint has completed a series of critical actions and improvements, including: Installing 32,000+ stronger, storm-resilient poles built to withstand extreme winds; Clearing higher-risk vegetation near 7,000+ miles of power lines; Installing 5,150+ automation devices capable of self-healing; and Undergrounding 400+ miles of power lines. Working towards our goal: Building the most resilient coastal grid in the countryIn the coming months and years, CenterPoint will continue working to strengthen the system and further improve reliability through a series of long-term investments, including the company's $3.2 billion Systemwide Resiliency Plan (SRP). The SRP is designed to dramatically improve resiliency against more extreme weather of the future; increase reliability for Houston customers, with a goal of reducing outages by nearly 1 billion minutes into 2029; and achieve our public goal of becoming the most resilient coastal grid in the country. For more information about CenterPoint's work to strengthen the system, visit About CenterPoint Energy, Inc. CenterPoint Energy, Inc. (NYSE: CNP) is a multi-state electric and natural gas delivery company serving approximately 7 million metered customers across Indiana, Minnesota, Ohio, and Texas. The company is headquartered in Houston and is the only Texas-domiciled investor-owned utility. As of March 31, 2025, the company had approximately $44 billion in assets. With approximately 8,300 employees, CenterPoint Energy and its predecessor companies have been serving customers for more than 150 years. For more information, visit Forward-Looking StatementThis news release, as well as the website pages related to the GHRI and SRP, includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. When used in this news release or the website pages related to the GHRI and SRP, the words 'anticipate,' 'believe,' 'continue,' 'could,' 'estimate,' 'expect,' 'forecast,' 'goal,' 'intend,' 'may,' 'objective,' 'plan,' 'potential,' 'predict,' 'projection,' 'should,' 'target,' 'will' or other similar words are intended to identify forward-looking statements. These forward-looking statements, which include statements regarding CenterPoint Energy's resiliency plans such as the GHRI and SRP, including with respect to timing, filings related thereto, anticipated benefits, and related matters, are based upon assumptions of management which are believed to be reasonable at the time made and are subject to significant risks and uncertainties. Actual events and results may differ materially from those expressed or implied by these forward-looking statements. Any statements in this news release or the website pages related to the GHRI and SRP regarding future events that are not historical facts are forward-looking statements. Each forward-looking statement contained in this news release or the website pages related to the GHRI and SRP speaks only as of the date of this release or the date that such statement is made, as applicable. Important factors that could cause actual results to differ materially from those indicated by the provided forward-looking information include risks and uncertainties relating to: (1) business strategies and strategic initiatives, acquisitions or dispositions of assets or businesses involving CenterPoint Energy or its industry; (2) CenterPoint Energy's ability to fund and invest planned capital, and the timely recovery of its investments; (3) financial market and general economic conditions; (4) the timing and impact of future regulatory, legislative and political actions or developments; and (5) other factors, risks and uncertainties discussed in CenterPoint Energy's Annual Report on Form 10-K for the fiscal year ended December 31, 2024 and CenterPoint's Quarterly Report on Form 10-Q for the quarter ended March 31, 2025 and other reports CenterPoint Energy or its subsidiaries may file from time to time with the Securities and Exchange Commission. For more information, contact:
Malaysian Reserve
34 minutes ago
- Malaysian Reserve
British Columbia Joins Other Provincial Public Drug Plans Now Reimbursing FOQUEST® on their Formulary for Attention Deficit Hyperactivity Disorder (ADHD)
TORONTO, July 23, 2025 /CNW/ – Elvium Life Sciences is pleased to announce the addition of FOQUEST® (methylphenidate hydrochloride controlled release capsules) to the British Columbia1 PharmaCare formulary and First Nations Health Authority (FNHA) Pharmacy Benefit. With provincial funding in place in British Columbia, FOQUEST® is now reimbursed from coast to coast on all provincial drug plans across Canada. 'Public funding in British Columbia ensures equitable access to ADHD treatments in BC,' said Juanita Beaudry, Executive Director of the Centre for ADHD Awareness (CADDAC) 'This latest approval now provides access across Canada to another treatment option for patients.' British Columbia now joins Alberta2, Saskatchewan3, Manitoba4, Ontario5, Quebec6, Atlantic Canada7,8,9,10, the Non-Insured Health Benefit Plan11 and Correctional Service Canada in providing public formulary coverage for FOQUEST® for the treatment of ADHD in patients aged six years and older. 'Elvium Life Sciences is very pleased that British Columbia has now included Foquest on the BC PharmaCare Formulary to give physicians an additional choice for their ADHD patients who require public coverage,' said Jodan Ratz, Country Medical Director at Elvium Life Sciences. 'We thank the province for its decision which now means that all ADHD patients aged six years of age and older have equivalent access to Foquest should this be the right treatment for them.' See the full Canadian Product Monograph for FOQUEST®12 The Product Monograph for FOQUEST® contains a Serious Warning and Precaution for drug dependence, emphasizing that abuse of FOQUEST® can lead to dependence. Healthcare professionals should assess the risk of abuse prior to prescribing FOQUEST®, including in patients with a history of drug dependence or alcoholism, and monitor for signs of abuse and dependence while patients are on therapy. FOQUEST® is a once-daily, long-acting methylphenidate controlled-release capsule for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients greater than or equal to six years of age. The maximum daily dose of FOQUEST® for children and adolescents (6 to <18 years old) is 70mg, and the maximum daily dose for adults (≥18 years old) is 100 mg. Adverse events observed with FOQUEST® treatment mainly reflect side effects commonly associated with methylphenidate use. Very common adverse events reported by patients treated with FOQUEST® were headache, insomnia, decreased appetite and abdominal pain. Most of the events were mild to moderate in severity. About Elvium Life Sciences Elvium Life Sciences is an independent associated company of Purdue Pharma (Canada), that focuses on specialty pharmaceutical products committed to providing treatment options for patients who suffer from the symptoms of Attention Deficit/Hyperactivity Disorder (ADHD) and products for ophthalmology. For more information, please visit FOQUEST® is a registered trademark of Purdue Pharma and is used under licence. References: 1. Available at: Accessed July 23, 2025 2. Available at: Accessed July 18, 2025 3. Available at: Accessed July 18, 2025 4. Available at: Accessed July 18, 2025 5. Available at: Accessed July 18, 2025 6. Available at: Accessed July 18, 2025 7. Available at: Accessed July 18, 2025 8. Available at: Accessed July 18, 2025 9. Available at: Accessed July 18, 2025 10. Available at: Accessed July 18, 2025 11. Available at: Accessed July 18, 2025. 12. Available at:
Malaysian Reserve
2 hours ago
- Malaysian Reserve
U.S. Lumber Coalition: Canada Employs Unfounded Scare Tactics in Attempt to Attack President Trump's Successful Trade Policies
The U.S. softwood lumber industry is a critical manufacturing industry essential to the national economic strength and the industrial resilience of the United States Canada's unfair trade in softwood lumber continues to be extremely harmful to U.S. producers and workers Continued strong trade law enforcement is paramount to bringing about fair pricing of lumber to support future capacity increases for U.S. self-reliance in lumber WASHINGTON, July 23, 2025 /PRNewswire/ — CNN recently published an article citing the Canadian Chamber of Commerce, backed by Canadian allied organizations such as the National Association of Homebuilders (NAHB), attacking President Trump's trade policies. The article claims that tariffs on Canadian building materials, with an emphasis on Canadian lumber imports, will drive up the cost of housing for U.S. consumers. This is incorrect. 'Claims by the National Association of Homebuilders that import duties, or possible future tariffs, against unfairly traded Canadian lumber imports would drive the housing affordability issue routinely have been proven wrong,' stated Zoltan van Heyningen, Executive Director of the U.S. Lumber Coalition, adding that 'an honest conversation about housing affordability, such as Prime Minister Carney engaged in when talking about housing affordability issues in Canada, would mainly focus on the cost of land, regulatory costs, labor, and high profitability rates of homebuilders.' 'President Trump's America First trade policies, which include the unyielding enforcement of U.S. trade laws against dumped and subsidized Canadian lumber imports, has resulted in a massive boost of U.S. production of softwood lumber to build American homes with American lumber produced by American workers,' stated Andrew Miller, Chair/Owner of Stimson Lumber Company. Increased U.S. capacity through the enforcement of the U.S. trade laws means that today the United States can supply the vast majority of its own lumber needs. U.S. mills have added 8.8 billion board feet of capacity since 2016 in the form of new mills and expansions of existing mills. The U.S. industry has produced 30 billion additional board feet of softwood lumber during this period. These increases have more than offset any decline in unfairly traded Canadian imports and are enough lumber to build two million new single-family homes. 'In order to continue seeing the massive growth of U.S. softwood lumber production capacity that we have seen over the last nine years as a result of U.S. trade law enforcement, it is essential that President Trump takes all necessary steps to downsizing Canada's unsustainable 8 billion board feet of excess lumber capacity that is stifling continued U.S. growth,' continued Miller. 'Canada's massive excess lumber capacity coupled with Canada needing to ship 60 to 70 percent of all their lumber production into the U.S. market in order to maintain that capacity is driving Canada to continue engaging in egregious unfair trade practices,' added Miller. 'Canadian softwood lumber companies, not U.S. consumers, directly pay the import duties through their U.S. subsidiaries. This is reflected in their financial statements, and is not a cost that they can pass on to the consumers in today's weak lumber market,' stated van Heyningen, adding that 'naturally, this is a fact that is overlooked by those seeking to attack President Trump's successful trade policies as it is an inconvenient truth.' 'To date, Canadian softwood lumber companies have paid an estimated 7 billion dollars to U.S. taxpayers, and will be on the hook for an additional estimated 1.3 billion dollars once the U.S. Department of Commerce issues its latest results in the ongoing antidumping and anti-subsidy trade cases,' explained van Heyningen. 'Canada is desperately trying to avoid paying their bill to the U.S. taxpayers and is pushing the outrageous scheme of using the collected duties slated for the U.S. Treasury as a bailout of the Canadian industry to secure jobs for Canadian workers. They are suggesting relieving Canada from having to pay future duties while continuing to dump their excess lumber into the U.S. market,' added van Heyningen. 'This is an affront to the principles of U.S. trade law enforcement, to U.S. taxpayers, and to U.S. industry and its workers who simply want to be able to compete on a level playing field.' U.S. lumber industry response to Canada's proposal that the United States terminate its trade cases against Canadian lumber in order to bail out the Canadian industry and secure jobs for Canadian workers. U.S. lumber industry and workers letter to President Trump on the need for continued strong enforcement of the U.S. trade laws to keep expanding U.S. lumber manufacturing and availability to build more American homes with American lumber. Enforcing U.S. trade laws helps increase the U.S. supply of lumber to build American homes, all without impacting the cost of a new home, as demonstrated by data from the National Association of Home Builders (NAHB) and Fastmarkets Random Lengths. About the U.S. Lumber Coalition The U.S. Lumber Coalition is an alliance of large and small softwood lumber producers from around the country, joined by their employees and woodland owners, working to address Canada's unfair lumber trade practices. Our goal is to serve as the voice of the American lumber community and effectively address Canada's unfair softwood lumber trade practices. The Coalition supports the full enforcement of the U.S. trade laws to allow the U.S. industry to invest and grow to its natural size without being impaired by unfairly traded imports. Continued full enforcement of the U.S. trade laws will strengthen domestic supply lines by maximizing long-term domestic production and lumber availability produced by U.S. workers to build U.S. homes. For more information, please visit the Coalition's website at CONTACT: Zoltan van Heyningenzoltan@ | 202-805-9133
